How to Help Cancer Research
Get Involved
Help us get one step closer to a cure. There are so many ways to lend a hand and improve the lives of patients and families impacted by ovarian and all gynecologic cancers.
How to Help Cancer Research
Get Involved
Help us get one step closer to a cure. There are so many ways to lend a hand and improve the lives of patients and families impacted by ovarian and all gynecologic cancers.
Our Numbers
OCRA is the world’s leading organization fighting ovarian and all gynecologic cancers on every front while supporting patients and their families and advocating on their behalf.
- Invested in research
- $140M
- In Federal Research and Education Funding
- $3.8B
- People supported each year
- 140K
Ways to Give
Join us as we drive innovation, offer hope, and invest in groundbreaking research that saves lives. Your generous support will allow us to continue to fund innovative research in our search for a cure, provide compassionate support to patients and their families, and advocate for everyone affected by ovarian and all gynecologic cancers.
Honor a Loved One
Partnership Opportunities
Sponsor a Scientist
Workplace Giving
Estate Planning
Volunteer & Engage
Whether advocating on Capitol Hill, being there for someone who is newly diagnosed, or helping educate the medical professionals of tomorrow about ovarian cancers, learn how your involvement can make a difference.
Fundraise
OCRA Heroes across the country are making a difference in the fight against ovarian and all gynecologic cancers by raising awareness and critical funds for OCRA’s research, advocacy, and patient support programs. Become an OCRA Hero and turn your passion into purpose.
Start a Fundraiser
Find a Fundraiser
Related Topics
FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
The Overview: March 2026
OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued
April Programs: New Offerings, Fresh Topics, and More
April is a full month at OCRA, with several new programs joining our ongoing lineup of workshops, educational sessions, and community events. Whether you’re looking for practical guidance, clinical information, or simply a chance to connect and create, there’s something here for you. New and Expanded Programs Advanced Care Planning Workshop Series April 6, 13, … Continued